Navigation Links
Atlas™

ProductsAtlas™
Company Welch Allyn Medical Products
Item Atlas™
Features 
  • ECGView either 3-lead or 5-lead electrocardiograph waveforms with the ability to change your view of the heart with just a button press. Includes heart rate display with programmable alarms.
  • PULSE OXIMETRYNellcor motion-tolerant pulse oximetry delivers accurate readings in challenging motion conditions and low perfusion. Includes a programmable low-alarm limit and pulse tone feature, as well as real-time plethysmograph waveform.
  • BLOOD PRESSUREUses the noninvasive, oscillometric technique for highly accurate determination of systolic, diastolic and mean arterial pressure (MAP). Special features include an automatic blood pressure mode with 7 measurement interval choices, and programmable alarm limits.
  • (optional) TEMPERATUREContinuously monitored using a skin surface temperature probe. Compatible with YSI Series 400 thermistor probes.
  • (optional) RESPIRATIONTransthoracic impedance technique with real-time waveform, adjustable sweep speed and programmable alarm limits. Completely upgradeable maximize your investment even if your needs change in the future.
  • Trend memory for up to 144 sets of patient data.
  • Optional dual-trace printer for both waveform and trend recording. Print on alarm immediately documents a patient alarm or invalid measurement, saving time during the procedure and charting process.
  • Optional battery for short-term transport or low power conditions.
  • Optional RS232 interface with Nurse Call capability.
    • Description The Welch Allyn Atlas monitor is a low-cost, multi-parameter monitor designed specifically for conscious sedation, IV anesthesia procedures, and surgery. The large display provides bright waveforms and LED numerics that are visible from across the room. The intuitive design allows users to learn how to operate the monitor in just minutes.

    Standard features include 3-lead or 5-lead ECG, heart/pulse rate, pulse oximetry (either Nonin® or Nellcor®), noninvasive blood pressure for systolic, diastolic and mean arterial pressure (MAP), automatic blood pressure mode, and programmable alarm limits.

    Optional features include temperature, respiration, ETCO2, an integrated printer for printouts of waveforms and trend analysis, a battery for short-term transport or low power conditions, an RS-232 port, and Nurse Call capability. These options provide the flexibility to configure the monitor according to your needs.

    The portable Atlas monitor can be set on a cart or countertop, wheeled on its own dedicated mobile stand, mounted on a wall, or carried using the integrated side handle.
    Info Welch Allyn Medical Products
    Customer Service: (800) 535-6663
    Web site: http://www.welchallyn.com/medical/

    Related medicine products :

    1. M.R.I. Vital Port Systems (standard size)
    2. Titanium Vital Port Systems (standard size)
    3. Petite Titanium Vital Port Systems
    4. Petite M.R.I. Vital Port Systems
    5. Mini Titanium Vital Port Systems
    6. Dual Chamber M.R.I. Vital Port Systems
    7. Dual Chamber Titanium Vital Port Systems
    8. Petite Dual Chamber Titanium Vital Port Systems
    9. Mini Titanium Vital-Port Systems for Peripheral Placement
    10. Vitality DS
    11. Vitality DS VR
    TAG: Atlas trade
    Tegagel hydrogel wound filler and Tegagel hydrogel wound filler with gauze are amorphous hydrogel dressings specially formulated to help provide a moist environment that has been shown to enhance wou
    ... physician preference card system as well as a per...ply management requirements of the surgical servic... with a broad array of inventory management capabi...suite supply and charge capture workflow. Regardle...
    ...rade; External Vacuum Therapy System restores sexu...ive and low cost vacuum therapy, coupled with its ..., makes it the ideal therapy for treating erectile... System causes penile rigidity that can be maintai...
    Easy to Use manual vacuum system features a pumping mechanism that can be operated with one hand.
    Medicine Products:
    (Date:5/13/2008)...-- United American Healthcare,Corporation (Nasdaq:...nagement services to a full-service managed care o...l results for its third fiscal quarter,ended March... million for the third fiscal,quarter ended March ...or,the third quarter of the prior fiscal year. The...
    (Date:5/13/2008)...re-FirstCall/ -- IRIDEX,Corporation (Nasdaq: IRIX...quarter of 2008 ended March 29, 2008., Revenue fo...8.7%,decrease from the $12.6 million reported for ...was $0.9 million or $0.10 per diluted share for th...f $4.9 million or $0.61 per,diluted share in the f...
    (Date:5/13/2008)... Ongoing; Company Prepares for, Potential 2008 Lau...llion in Quarter, G...iddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ),...d commercializing novel anti-infective products, t...or the quarter ended March 31,2008., MiddleBrook...
    (Date:5/13/2008)... the poor from improving, study finds , ,...of care at hospitals that treat poor and underserv... lagging well behind hospitals that do not serve t...tals, which rely on state and federal funding from... to improve the quality of care at the same rate t...
    Breaking Medicine News(10 mins):Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 2Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 3Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 4Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 5Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 6Health News:United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results 7Health News:IRIDEX Reports First Quarter 2008 Financial Results 2Health News:IRIDEX Reports First Quarter 2008 Financial Results 3Health News:IRIDEX Reports First Quarter 2008 Financial Results 4Health News:IRIDEX Reports First Quarter 2008 Financial Results 5Health News:IRIDEX Reports First Quarter 2008 Financial Results 6Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 13Health News:Quality Lags at Safety-Net Hospitals 2Health News:Quality Lags at Safety-Net Hospitals 3
    ...acteria known as E. coli 0157:H7 causes some of th...en and adults. Infections with this organism are o...udy shows using antibiotics to treat children with...he risk of developing a potentially deadly liver d...
    ...ysfunction is associated with loss of libido, low ...men who have attained their menopause or whose ova...Dehydroepiandosterone(DHEA), may serve as an effec...n, according to a study released at the 96th annua...
    ...cal Association (IMA) is embarking on an exercise ...country, according to Dr. Sanjiv Malik, Honorary S...so entered into an alliance with ORGMARG to create...ners in the country, be it allopathy or homeopathy...
    ...isclosure, Dr. Murali Ankem, a resident in Urology... University of New Jersey Medical and Dental Schoo...sed in prostate cancer treatment can migrate to ot...s. In a procedure called Brachytherapy, tiny metal...
    Other Medicine News:
    (Date:5/13/2008)...., May 13 /- Dried blood spots are em...serum collection and transport,for blood tests. In...l of,Diabetes Science and Technology (2008; 2(2):2...e use of dried blood spots is a "powerful tool", f...developing countries with,limited health budgets.,...
    (Date:5/13/2008)... and BARCELONA, Spain, May 13 /PRNewswire-FirstCal...today welcomed two-year results,from the SPIRIT II...roven,long-term safety and efficacy of the market-...oronary Stent System and reinforce the growing bod... V (PROMUS(TM)),Everolimus-Eluting Coronary Stent ...
    (Date:5/13/2008)...ted with XIENCE V in SPIRIT III Trial Experience B... Stent Thrombosis than Patients ... 13 /- Long-term data,prese...trial, Abbott,s U.S.,pivotal trial studying the XI...m, demonstrated that XIENCE V continues to deliver...
    (Date:5/13/2008)...LIS, France, May 13 /- NicO...& Co., Inc. has initiated the,first in a series of...ertensive patients, under the companies, collabora...g antihypertensive agents using NicOx,proprietary...elected from,the companies, joint research program...
    Breaking Medicine Technology:Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening 2SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 2SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 3SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3African medical research and training receives Wellcome boost 16519 1African medical research and training receives Wellcome boost 16519 2SAPPHIRE trial shows long term benefit of carotid stenting as alternative to surgery 16517 1SAPPHIRE trial shows long term benefit of carotid stenting as alternative to surgery 16517 2SAPPHIRE trial shows long term benefit of carotid stenting as alternative to surgery 16517 3Study Showed Minimally Invasive Surgery Reduced Risk of Hospital Acquired Infections Compared to Open Surgery 16516 1Study Showed Minimally Invasive Surgery Reduced Risk of Hospital Acquired Infections Compared to Open Surgery 16516 2Study Showed Minimally Invasive Surgery Reduced Risk of Hospital Acquired Infections Compared to Open Surgery 16516 3Rejuvasun 28TM 29 With Omnilux 28TM 29 3A Industry First to Feature FDA Cleared Clinically Proven Light Therapy Technology 16514 1Rejuvasun 28TM 29 With Omnilux 28TM 29 3A Industry First to Feature FDA Cleared Clinically Proven Light Therapy Technology 16514 2Rejuvasun 28TM 29 With Omnilux 28TM 29 3A Industry First to Feature FDA Cleared Clinically Proven Light Therapy Technology 16514 3
    ...RE)--Jun 18, 2007 - Advanced Viral,Research Corp. ...company, announced today that preliminary findings...ow topical treatment with AVR118,appears to have c...ess associated with surgical incisions or dermatol...ological study is evaluating the,activity of a top...
    ...Influenza Conference , HIGH WYCOMBE, UK 18th June ...ing how a new flu vaccine has the potential,to pro...andemic and,annual, was presented today by PepTcel...a VI (Options) Conference, in Toronto,Canada. , T...n the,European Journal of Immunology, showed how m...
    Other Medicine Technology:Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 5